358 related articles for article (PubMed ID: 24990403)
1. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
3. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
Lee SM; Bae SK; Jung SJ; Kim CK
Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
[TBL] [Abstract][Full Text] [Related]
4. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of multiple metabolic and heterogeneity parameters of
Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic and predictive efficacy of
Guo Y; Zhu H; Yao Z; Liu F; Yang D
Eur J Radiol; 2021 Aug; 141():109792. PubMed ID: 34062472
[TBL] [Abstract][Full Text] [Related]
7. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
[TBL] [Abstract][Full Text] [Related]
9. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
11. Correlation between EGFR mutation status and F
Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
[TBL] [Abstract][Full Text] [Related]
12. Can
Du B; Wang S; Cui Y; Liu G; Li X; Li Y
BMJ Open; 2021 Jun; 11(6):e044313. PubMed ID: 34103313
[TBL] [Abstract][Full Text] [Related]
13. Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images.
Shiri I; Amini M; Nazari M; Hajianfar G; Haddadi Avval A; Abdollahi H; Oveisi M; Arabi H; Rahmim A; Zaidi H
Comput Biol Med; 2022 Mar; 142():105230. PubMed ID: 35051856
[TBL] [Abstract][Full Text] [Related]
14. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of intratumor metabolic and heterogeneity parameters on [
Ni M; Wang S; Liu X; Shi Q; Zhu X; Zhang Y; Xie Q; Lv W
Jpn J Radiol; 2023 Feb; 41(2):209-218. PubMed ID: 36219311
[TBL] [Abstract][Full Text] [Related]
16. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
17. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
[TBL] [Abstract][Full Text] [Related]
18. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
[TBL] [Abstract][Full Text] [Related]
20. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]